We noticed JavaScript is turned off in your browser settings. For a better viewing experience, enable JavaScript. If you're unsure of how to do this, click here to download a new browser.

FOR PREVIEW ONLY (Print)

Jennelle Hodge, PhD, FACMG

Associate Director, Cytogenetics Laboratory

Associate Professor, Pathology and Lab Medicine

Associate Professor, Biomedical Sciences

Scientific Director, Molecular Pathology Laboratory

Jennelle Hodge, PhD, FACMG

Associate Director, Cytogenetics Laboratory

Associate Professor, Pathology and Lab Medicine

Associate Professor, Biomedical Sciences

Scientific Director, Molecular Pathology Laboratory

The research interests of Jennelle Hodge, FACMG, PhD, includes development and implementation of innovative technologies for molecular and cytogenomic clinical diagnostics; mining of genomic data for genotype and phenotype correlation; and genetics of solid tumors, particularly prostate cancer and uterine neoplasms.

  • Doctorate: Medical College of Wisconsin, 1999-2003
  • Fellowship: Harvard Medical School, 2003-2005 (Clinical Cytogenetics)
  • Post Doctorate: Brigham and Women's Hospital, 2003-2007
  • Fellowship: Harvard Medical School, 2005-2006 (Clinical Molecular Genetics)
  • Annual Meeting Program Committee, American College of Medical Genetics, 2015-present
  • Myeloid Microarray Working Group, Cancer Genetics Consortium, 2015-present
  • Fellow of the American College of Medical Genetics Status Granted, 2010
  • Reviewer of: American Journal of Medical Genetics; American Journal of Obstetrics and Gynecology; Cancer Genetics; European Journal of Human Genetics; Molecular Human Reproduction; PLoS One; Genetics in Medicine; Molecular Cytogenetics; others
  • Member of: American Society of Human Genetics; Association of Molecular Pathologists; American College of Medical Genetics; Cancer Genomics Consortium
  • Hodge JC, Pearce KE, Wang X, Wiktor AE, Oliveira AM, Greipp PT. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases. Mod Pathol. 2013;27(1):113-127.
  • Hodge JC, Pearce KE, Clayton AC, Taran FA, Stewart EA. Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. Am J Obstet Gynecol. 2014;210(6):572.e1-7.
  • Hodge JC, Bedroske PB, Pearce KE, Sukov WR. Molecular cytogenetic analysis of JAZF1, PHF1 and YWHAE in endometrial stromal tumors: Discovery of genetic complexity by FISH. J Mol Diag. In press.
  • Sukov WR, Hodge JC, Lohse CM, Akre MK, Leibovich BC, Thompson H, Cheville JC. ALK Alterations in adult renal cell carcinoma: Frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Modern Pathol. Mod Pathol. 2012 Nov;25(11):1516-1525.
  • Hodge JC, Kim TM, Dreyfuss JM, Somasundaram P, Christacos NC, Rousselle M, Quade BJ, Park PJ, Stewart EA, Morton CC. Expression profiling of uterine leiomyomata cytogenetic subgroups reveals distinct signatures in matched myometrium: transcriptional profilingof the t(12;14) and evidence in support of predisposing genetic heterogeneity. Hum Mol Genet. 2012 May 15;21(10):2312-29.
  • Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A, and Lindholm PF. Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. Cancer Res. 2003 Mar 15;63(6):1359-1364.

Show moreShow less

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.

Send Email to Jennelle Hodge, PhD, FACMG